Cabinet Office to Organize Society 5.0 Expo to Showcase Japan’s Advanced Technologies and Achievements
14.7.2021 09:00:00 EEST | Business Wire | Press release
The Government of Japan’s Cabinet Office announced that it will organize the Society 5.0 Expo jointly with the Japan Agency for Marine-Earth Science and Technology (JAMSTEC) from 15 July at TOKYO SKYTREE TOWN® in Tokyo, Japan. This is expected to be Japan’s first major expo to focus on Society 5.0. The expo will also be viewable online with multilingual explanations for the global audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713006253/en/
[From upper-left] SHINKAI 6500, HAYABUSA2, Wearable Cyborg, Active scope camera for rescue [From lower-left] Ultra-thin and flexible tough polymer, Rescue robot, Small synthetic-aperture radar satellite (SAR), Communication robot, Flying car, Level-3 autonomous vehicle (Photo: Business Wire)
The expo will showcase the Society 5.0 concept proposed by the Japanese government as a highly desirable future society. The concept envisions the creation of a human-centered society in which all industries and other areas of society adopt AI, IoT, robots, big data and other innovative technologies to overcome critical challenges. The Cabinet Office’s 6th Science, Technology and Innovation Basic Plan covering fiscal 2021 to 2025 sets forth the direction of science, technology and innovation policies to secure sustainability, resilience and the well-being of diverse individuals.
The expo will present achievements being realized through national projects focused on increasing innovation in society, including the cross-ministerial strategic innovation promotion program (SIP) and the ImPACT program for stimulating high-risk, high-impact R&D. Japan’s scientific and technological aspirations will be conveyed through numerous displays of advanced technologies.
Specifically, some 50 leading Japanese companies, universities and organizations will exhibit approximately 200 products and research achievements that are expected to contribute not only to Society 5.0 but also the UN’s Sustainable Development Goals. The exhibits will cover fields such as mobility, healthcare and caregiving, manufacturing, agriculture, food, disaster prevention and energy, including:
- Asteroid-explorer Hayabusa2’s returned capsule
- Full-scale model of SHINKAI 6500 submersible piloted to 6,500 meters undersea
- SkyDrive flying car
- Honda Legend Level-3 autonomous vehicle with high-definition 3D mapping
- Model of small synthetic-aperture radar satellite system for on-demand launches and instant observation
- HAL wearable cyborg that transmits brain signals to human muscles for assistance with physical functions
- Disaster-prevention systems for heavy rain and tornado forecasting and ICT-based information sharing
- Smart agriculture technology, such as an automated water supply and drainage system
International viewers will be welcome to enjoy the many exhibits viewable online via mobile devices and PCs, supported with explanations available in a number of languages. The organizers will be pleased to present the virtual exhibition as an opportunity for the global community to learn more about Japan’s forward-looking Society 5.0 concept.
Exhibits will be grouped under the follow themes:
Stage 1 Prologue
The opening theme will present a full-scale model of the SHINKAI 6500 research submersible and a Dagik Earth three-dimensional digital globe, etc. Satellite-based technologies that are being deployed on a practical working basis in various sectors also will be introduced.
Stage 2 Science Frontiers—Space and Ocean
Exhibits of Japan's world-class space-exploration technology will include models of the International Space Station, the "Kibo" Japanese Experiment Module, a full-scale rocket engine, and the Hayabusa2 return capsule.
Exhibits of Japan’s ocean exploration and environmental-simulation technology will include autonomous underwater vehicles for exploring hydrothermal vents and ocean-floor resources and advanced solutions for ocean research.
Stage 3 5.0 Society of the Future
Science and technologies developed through Japan’s SIP and ImPACT programs and how they will help to enhance life in five areas: 1) 100-year lifespans, 2) Mobility and social interaction, 3) Infrastructure for more resilient and safer life, 4) Human- and earth-friendly lifestyles and 5) Advanced manufacturing. Exhibits will include automated solutions such as robots, vehicles and drones, disaster-prevention systems such as AI for infrastructure inspections, robotic industrial borescopes, next-generation energy and resources such as ammonia fuel and ocean-floor minerals, and advanced materials such as synthetic spider silk and strong but flexible ultra-thin polymers.
Stage 4 Trajectory toward Society 5.0
The evolution of human civilization will be presented through videos and other visuals portraying Society 1.0 (hunting & gathering), 2.0 (agriculture), 3.0 (industry) and 4.0 (information) as well as 5.0 (at TOKYO SKYTREE® Tembo Galleria, the closest point to space in Tokyo).
Stage 5 Society 5.0 Theater
Films from the Japan Aerospace Exploration Agency (JAXA) and JAMSTEC will be aired. Also, researchers and experts will give presentations about science, oceans, disaster prevention and ICT for advanced technology and innovation.
Please download official images from here.
Outline of Society 5.0 Expo
|
Organizers |
Cabinet Office and Japan Agency for Marine-Earth Science and Technology (JAMSTEC) |
|
|
Venue |
Exhibition areas within TOKYO SKYTREE TOWN |
|
|
|
- Pavilion at TOKYO SKYTREE TOWN Sky Arena (4F) |
|
|
|
- TOKYO SKYTREE TOWN Solamachi Square (1F) |
|
|
|
- TOKYO SKYTREE Group Floor (1F) |
|
|
|
- TOKYO SKYTREE Tembo Galleria |
|
|
|
- TOKYO SKYTREE TOWN campus of Chiba Institute of Technology |
|
|
|
|
|
|
Dates |
15 July to 5 September 2021 |
|
|
|
- Physical exhibitions by enterprises (15 July to 19 July) |
|
|
|
- Physical exhibitions by other organizations (15 July to 28 July) |
|
|
|
- Sub-exhibition by posters and videos (15 July to 5 September) |
|
|
|
- Virtual exhibition (17 July to 5 September) with multi-language explanations
|
|
|
Admission |
Free (Admission to sub-exhibition by ticket, sold at TOKYO SKYTREE Tembo Galleria) |
|
|
Exhibitors and partners |
Please refer to the list on the official website |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006253/en/
Contact information
Society 5.0 media inquiries
Weber Shandwick
Mayuko Harada (+81-90-9006-4968)
Rina Uesugi (+81-90-2280-0041)
E-mail: society5.0expo@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom